So anything over 30%orr and 6mo duration of response will be a big win. So far, with and without ALC biomarker use, the data of the first 13 patients beat these bar. At lugano meeting, only early data of 7 patients recruited will be presented : I would like to see DCR > 50% with 1-2 response and 1-2 stable disease.
Market Data 
Markets 
AI
